Newcastle and Dundee University researchers have uncovered an alternative path of how the breast cancer drug palbociclib drives malignant cells into cell death, senescence. (medicalxpress.com)
«Patients with HR +, HER2 - metastatic breast cancer whose disease have progressed after endocrine therapy have significant unmet needs, and we're pleased with the results of this study that demonstrate the potential for palbociclib as an important treatment option for this patient population.» (sciencedaily.com)
► In a news feature in this week's Science, Ken Garber described the surprisingly, frustratingly messy path of palbociclib, one of the most promising cancer treatments to come along in years, from its conception in 1995 through its recent, successful phase - II clinical trial. (sciencemag.org)